Melittin and Breast Cancer: A Brief Review of the Evidence
Keywords:
Melittin, Breast cancer, Chemotherapy, Cancer, TumorAbstract
Bee venom is commonly used for treating ailment including pain and tumor. There are various investigations concerning
melittin in terms of tumors treatment or antitumor activity. Melittin consists of 26 amino acid residues, mostly with hydrophobic
or at least uncharged side chains, except for the C-terminal region, and the principal function of melittin as a component of bee
venom is to cause pain and destruction of the tissue of intruders that threaten a beehive. There are various shreds of evidence
regarding the effect of melittin on cancer or tumor cells. The aim of this review study was to investigate the effects of melittin on
breast cancer. Studies with inclusion criteria from 2016 were included in this study. The second reason for death in women is breast
cancer. The development of breast cancer is a multi-step process involving multiple cell types, and its prevention remains challenging
in the world. By various biochemical and molecular mechanisms, Melittin could lead to a reduction of tumor size, prevention of
metastasis, and in some cases cancer treatment. It was particularly significant cytotoxicity on damaging breast cancer cells. Some
pieces of evidence also suggested that for diminishing the hemolytic and allergic reactions and fulfilling the efficacy of treatment
outcome combine melittin with nanoparticles or chemotherapeutic agents. Melittin has positive effects on several types of cancer,
such as renal, lung, liver, prostate, bladder, breast, thyroid, and melanoma. However, it should not be underestimated that most
studies are in vitro and in vivo; therefore, more randomized control trials are required.
References
Huh JE, Baek YH, Lee MH, Choi DY, Park DS, et al. “Bee venom inhibits tumor angiogenesis and metastasis by inhibiting tyrosine phosphorylation of VEGFR-2 in LLC-tumor-bearing mice”. Cancer lett 292(2010): 98-110.
Jung GB, Huh JE, Lee HJ, Kim D, Lee GJ, et al. “Anti-cancer effect of bee venom on human MDA-MB-231 breast cancer cells using Raman spectroscopy.” Biomed Opt Express 9(2018): 5703-5718.
Rady I, Siddiqui IA, Rady M, Mukhtar H. “Melittin, a major peptide component of bee venom, and its conjugates in cancer therapy”. Cancer lett 402(2017): 16-31.
Doublet V, Poeschl Y, Gogol-Döring A, Alaux C, Annoscia D, et al. “Unity in defence: Honeybee workers exhibit conserved molecular responses to diverse pathogens”. BMC genomics 18(2017): 1-7.
Liu CC, Hao DJ, Zhang Q, An J, Zhao JJ, et al. “Application of bee venom and its main constituent melittin for cancer treatment”. Cancer chemotherapy and pharmacology 78(2016): 1113-1130.
http://repository.limu.edu.ly/handle/123456789/1738
Gajski G, Garaj-Vrhovac V. “Melittin: A lytic peptide with anticancer properties”. Environmental toxicology and pharmacology 36(2013): 697-705.
Qian CY, Wang KL, Fang FF, Gu W, Huang F, et al. “Triple-controlled oncolytic adenovirus expressing melittin to exert inhibitory efficacy on hepatocellular carcinoma.” Int J Clin Exp Pathol 8(2015): 10403.
Huh JE, Kang JW, Nam D, Baek YH, Choi DY, et al. “Melittin suppresses VEGF-A-induced tumor growth by blocking VEGFR-2 and the COX-2-mediated MAPK signaling pathway.” J Nat Prod 75(2012): 1922-1929.
Chaisakul J, Hodgson WC, Kuruppu S, Prasongsook N. “Effects of animal venoms and toxins on hallmarks of cancer”. Journal of Cancer 7(2016): 1571.
Sun YS, Zhao Z, Yang ZN, Xu F, Lu HJ, et al. “Risk factors and preventions of breast cancer”. International journal of biological sciences 13(2017): 1387-1397.
Feng RM, Zong YN, Cao SM, Xu RH. “Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?”. Cancer Communications 39(2019): 22.
Gaowa A, Horibe T, Kohno M, Sato K, Harada H, et al. “Combination of hybrid peptide with biodegradable gelatin hydrogel for controlled release and enhancement of anti-tumor activity in vivo”. J Control Release 176(2014): 1-7.
Zhao H, Qin X, Yang D, Jiang Y, Zheng W, et al. “The development of activatable lytic peptides for targeting triple negative breast cancer”. Cell Death Discov 3(2017): 1-8.
Soman NR, Lanza GM, Heuser JM, Schlesinger PH, Wickline SA . “Synthesis and characterization of stable fluorocarbon nanostructures as drug delivery vehicles for cytolytic peptides”. Nano Lett 8 (2008): 1131-1136.
Yang L, Cui F, Shi K, Cun D, Wang R. “Design of high payload PLGA nanoparticles containing melittin/sodium dodecyl sulfate complex by the hydrophobic ion-pairing technique”. Drug Dev Ind Pharm 35 (2009): 959-968.
Zetterberg MM, Reijmar K, Pranting M, Engstrom A, Andersson DI, et al. “PEG-stabilized lipid disks as carriers for amphiphilic antimicrobial peptides”. J Control Release 156 (2011): 323-328.
Dang YQ, Li HW, Wu Y. “Construction of a supramolecular forster resonance energy transfer system and its application based on the interaction between Cy3-labeled melittin and phosphocholine encapsulated quantum dots”. ACS Appl Mater Interfaces 4(2012): 1267- 1272.
Huang C, Jin H, Qian Y, Qi S, Luo H, et al. “Hybrid melittin cytolytic peptide-driven ultrasmall lipid nanoparticles block melanoma growth in vivo”. ACS Nano 7 (2013): 5791–5800.
Gajski G, Garaj-Vrhovac V. “Melittin: A lytic peptide with anticancer properties”. Environmental toxicology and pharmacology 36(2013): 697-705.
Tacón A. “Melittin and cancer”. Cancer Cells 8 (2016): 10-12.
Hematyar M, Soleimani M, Es-Haghi A, Rezaei Mokarram A. “Synergistic co-delivery of doxorubicin and melittin using functionalized magnetic nanoparticles for cancer treatment: Loading and in vitro release study by LC–MS/MS”. Artif Cells Nanomed Biotechnol 46(2018): S1226-S1235.
El Bakary NM, Alsharkawy AZ, Shouaib ZA, Barakat EM. “Role of Bee Venom and Melittin on Restraining Angiogenesis and Metastasis in γ-Irradiated Solid Ehrlich Carcinoma-Bearing Mice”. Integrative Cancer Therapies 19(2020): 1534735420944476.
Raveendran R, Chen F, Kent B, Stenzel MH. “Estrone-Decorated Polyion Complex Micelles for Targeted Melittin Delivery to Hormone- Responsive Breast Cancer Cells”. Biomacromolecules 21(2020): 1222- 1233.
Zhou Y, Zhang S, Chen Z, Bao Y, Chen AT, et al. “Targeted Delivery of Secretory Promelittin via Novel Poly (lactone‐co‐β‐amino ester) Nanoparticles for Treatment of Breast Cancer Brain Metastases”. Advanced Science 7(2020): 1901866.
Khamis AA, Ali EM, Abd El-Moneim MA, Abd-Alhaseeb MM, El-Magd MA, et al. “Hesperidin, piperine and bee venom synergistically potentiate the anticancer effect of tamoxifen against breast cancer cells”. Biomed Pharmacother 105(2018): 1335-1343.
Huh JE, Kang JW, Nam D, Baek YH, Choi DY, et al. “Melittin suppresses VEGF-A-induced tumor growth by blocking VEGFR-2 and the COX-2-mediated MAPK signaling pathway”. Journal of natural products 75(2012): 1922-1929.
Gao D, Zhang J, Bai L, Li F, Dong Y, et al. “Melittin induces NSCLC apoptosis via inhibition of miR-183”. OncoTargets and therapy 11(2018): 4511.
Rajabnejad SH, Mokhtarzadeh A, Abnous K, Taghdisi SM, Ramezani M, et al. “Targeted delivery of melittin to cancer cells by AS1411 antinucleolin aptamer”. Drug Development and Industrial Pharmacy 44(2018): 982-987.
Yazdian-Robati R, Arab A, Ramezani M, Rafatpanah H, Bahreyni A, et al. “Smart aptamer-modified calcium carbonate nanoparticles for controlled release and targeted delivery of epirubicin and melittin into cancer cells in vitro and in vivo”. Drug Dev Ind Pharm 45(2019): 603- 610.
Liu M, Wang H, Liu L, Wang B, Sun G. “Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy. Journal of translational medicine 14(2016): 1-2.
Badria F, Fathy HM, Fatehe AS, Elimam DM, Ghazy MG. “Evaluate the cytotoxic activity of honey, propolis, and bee venom from different localities in Egypt against liver, breast, and colorectal cancer”. J Apither 2(2017): 1-4.
He B, Tan T, Wang H, Hu H, Wang Z, et al. “Rational Design of Tumor Microenvironment‐Activated Micelles for Programed Targeting of Breast Cancer Metastasis”. Advanced Functional Materials 28(2018): 1705622.
Kong GM, Tao WH, Diao YL, Fang PH, Wang JJ, et al. “Melittin induces human gastric cancer cell apoptosis via activation of mitochondrial pathway”. World journal of gastroenterology 22(2016): 3186-3195.
Ke M, Dong J, Wang Y, Zhang J, Zhang M, et al. “MEL-pep, an analog of melittin, disrupts cell membranes and reverses 5-fluorouracil resistance in human hepatocellular carcinoma cells”. The international journal of biochemistry & cell biology 1(2018): 39-48.
Nikodijević DD, Milutinović MG, Cvetković DM, Ćupurdija MĐ, Jovanović MM, et al. “Impact of bee venom and melittin on apoptosis and biotransformation in colorectal carcinoma cell lines”. Toxin Reviews 22(2019): 1-8.
Jin Z, Yao J, Xie N, Cai L, Qi S, et al. “Melittin constrains the expression of identified key genes associated with bladder cancer”. Journal of immunology research 3(2018): 1-16.
Alonezi S, Tusiimire J, Wallace J, Dufton MJ, Parkinson JA, et al. “Metabolomic profiling of the effects of melittin on cisplatin resistant and cisplatin sensitive ovarian cancer cells using mass spectrometry and biolog microarray technology”. Metabolites 6(2016): 35.
Zarrinnahad H, Mahmoodzadeh A, Hamidi MP, Mahdavi M, Moradi A, et al. “Apoptotic effect of melittin purified from iranian honey bee venom on human cervical cancer hela cell line”. International journal of peptide research and therapeutics 24(2018): 563-570.
Lim HN, Baek SB, Jung HJ. “Bee venom and its peptide component melittin suppress growth and migration of Melanoma Cells via inhibition of PI3K/AKT/mTOR and MAPK pathways”. Molecules 24(2019): 929.
Qin G, Chen Y, Li H, Xu S, Li Y, et al. “Melittin inhibits tumor angiogenesis modulated by endothelial progenitor cells associated with the SDF-1α/CXCR4 signaling pathway in a UMR-106 osteosarcoma xenograft mouse model”. Molecular Medicine Reports 14(2016): 57- 68.
Shaw P, Kumar N, Hammerschmid D, Privat-Maldonado A, Dewilde S, et al. “Synergistic effects of melittin and plasma treatment: A promising approach for cancer therapy”. Cancers 11(2019): 1109.
Ceremuga M, Stela M, Janik E, Gorniak L, Synowiec E, et al. “Melittin—A Natural Peptide from Bee Venom Which Induces Apoptosis in Human Leukaemia Cells”. Biomolecules 10(2020): 247.
Gajski G, Domijan AM, Žegura B, Štern A, Gerić M, et al. “Melittin induced cytogenetic damage, oxidative stress and changes in gene expression in human peripheral blood lymphocytes”. Toxicon 110(2016): 56-67.
Zhang Z, Zhang H, Peng T, Li D, Xu J. “Melittin suppresses cathepsin S-induced invasion and angiogenesis via blocking of the VEGF-A/ VEGFR-2/MEK1/ERK1/2 pathway in human hepatocellular carcinoma”. Oncology letters 11(2016): 610-618.
Biniecka PA, Jaworski SŁ, Bugajska Z, Daniluk KA. “Carbon nanoparticles as transporters of melittin to glioma grade IV U87 cells in in vitro model”. Annals of Warsaw University of Life Sciences- SGGW. Animal Science 2017: 56.
HUANG S, Jianhua WA, Xiaozhong WA, Chenghong LI. “Melittin: A key composition of honey bee venom with diverse pharmaceutical function”. International Conference on Biological Engineering and Pharmacy 2016 (BEP 2016) 2016.
Tipgomut C, Wongprommoon A, Takeo E, Ittiudomrak T, Puthong S, et al. “Melittin Induced G1 Cell Cycle Arrest and Apoptosis in Chago-K1 Human Bronchogenic Carcinoma Cells and Inhibited the Differentiation of THP-1 Cells into Tumour-Associated Macrophages”. Asian Pacific Journal of Cancer Prevention 19(2018): 3427
Moghadam ER, Ang HL, Asnaf SE, Zabolian A, Saleki H, et al. “Broad-Spectrum Preclinical Antitumor Activity of Chrysin: Current Trends and Future Perspectives”. Biomolecules 10(2020): 1374
